Financial News
Press Releases about Lobe Sciences Ltd
![](https://mms.businesswire.com/media/20240815293620/en/2217775/5/Lobe-Sciences.jpg)
![](https://mms.businesswire.com/media/20240812177123/en/2214240/22/Lobe-Sciences.jpg)
![](https://mms.businesswire.com/media/20240604440324/en/2150647/22/New_Lobe_Logo.jpg)
![](https://mms.businesswire.com/media/20240603736614/en/2147861/22/New_Lobe_Logo.jpg)
![](https://mms.businesswire.com/media/20240531269556/en/2146050/22/New_Lobe_Logo.jpg)
![](https://mms.businesswire.com/media/20240530514965/en/2144567/22/New_Lobe_Logo.jpg)
![](https://mms.businesswire.com/media/20240521784730/en/2137384/22/New_Lobe_Logo.jpg)
![](https://mms.businesswire.com/media/20240108837220/en/1991909/22/New_Lobe_Logo.jpg)
Lobe Sciences Provides Company Review of 2023
January 08, 2024
From Lobe Sciences Ltd.
Via Business Wire
![](https://mms.businesswire.com/media/20231207780834/en/1962656/22/New_Lobe_Logo.jpg)
Lobe Sciences Provides Update on L-130 Clinical Program
December 07, 2023
From Lobe Sciences Ltd.
Via Business Wire
![](https://mms.businesswire.com/media/20231205299145/en/1959854/22/New_LOBE_Sciences_Logo.jpg)
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
December 05, 2023
From Lobe Sciences Ltd.
Via Business Wire
![](https://www.businesswire.com/images/bwlogo_extreme.png)
From Lobe Sciences Ltd.
Via Business Wire
![](https://mms.businesswire.com/media/20230627175001/en/1829205/5/LOBE_Sciences_Logo.jpg)
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
June 27, 2023
From Lobe Sciences Ltd.
Via Business Wire
![](https://mms.businesswire.com/media/20230607005208/en/1812602/5/LOBE_Sciences_Logo.jpg)
![](https://mms.businesswire.com/media/20230517005418/en/1796368/22/Lobe_Logo.jpg)
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
Topics
Economy
Exposures
Supply Chain
Exposures
Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
January 19, 2023
Via AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
September 01, 2022
Via Newsfile
Topics
Cannabis
Exposures
Cannabis
Lobe Sciences Provides Corporate Update to Investors and Stakeholders
September 13, 2021
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.